Last updated on March 2020

A Study Assessing the Safety Tolerability and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Brief description of study

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control.

Clinical Study Identifier: NCT03972709

Find a site near you

Start Over

Long Is. Vitreoretinal Consult

Great Neck, NY United States
  Connect »

Ophthalmic Consultants of Long Island

Rockville Centre, NY United States
  Connect »